Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 13Rectal Neoplasms 10Esophageal Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Esophageal Squamous Cell Carcinoma 6Uterine Cervical Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Colonic Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Liposarcoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Multiple Myeloma 2Melanoma 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × Neoadjuvant Therapy × Clear all
NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Sandoz

Phase 3 Terminated
52 enrolled
Dermatologic

Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡